Buscar
TG Therapeutics Inc
TGTXAñadir a la lista de seguimiento
55.900USD
+0.180+0.32%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
8.56BCap. mercado
17.46P/E TTM
Más Datos de TG Therapeutics Inc Compañía
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Información de TG Therapeutics Inc
Símbolo de cotizaciónTGTX
Nombre de la empresaTG Therapeutics Inc
Fecha de salida a bolsaDec 14, 1995
Director ejecutivoWeiss (Michael S)
Número de empleados338
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 14
Dirección3020 Carrington Mill Blvd., Suite 475
CiudadMORRISVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27560-5435
Teléfono18775758489
Sitio Webhttps://www.tgtherapeutics.com/
Símbolo de cotizaciónTGTX
Fecha de salida a bolsaDec 14, 1995
Director ejecutivoWeiss (Michael S)
Ejecutivos de TG Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de TG Therapeutics Inc?
Los cinco principales accionistas de TG Therapeutics Inc son: Mr. Michael S. Weiss, J.D.
¿Cuántas instituciones poseen acciones de TG Therapeutics Inc (TGTX)?
A fecha de 2026Q1, 760 instituciones poseen acciones de TG Therapeutics Inc, con un valor de mercado combinado de aproximadamente 122.50M, lo que representa el 80.02% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 4398281.00.
¿Cuál es la mayor fuente de ganancias de TG Therapeutics Inc?
El 2026Q1, el segmento empresarial Total product revenue, net generó la ganancia más alta para TG Therapeutics Inc, ascendiendo a 606.93M y representando el 98.48% de la ganancia total.
